Clinical Trial Update: Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS) [Phase 4]

View source ↗

Summary

Phase 4 trial update describing patient-reported outcomes for kidney transplant recipients who were converted to Myfortic (enteric-coated mycophenolate mofetil)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant

Drugs mentioned

• MYFORTIC (MYCOPHENOLIC ACID)

Snippet

Sponsor: Foothills Medical Centre | Conditions: Kidney Transplant | Phase 4 | Status: UNKNOWN